- Home
- IBOC vs CRSP Comparison
IBOC vs CRSP Comparison
Compare IBOC & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBOC
- CRSP
- Stock Information
- Founded
- IBOC 1966
- CRSP 2013
- Country
- IBOC United States
- CRSP Switzerland
- Employees
- IBOC N/A
- CRSP 393
- Industry
- IBOC Major Banks
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IBOC Finance
- CRSP Health Care
- Exchange
- IBOC Nasdaq
- CRSP Nasdaq
- Market Cap
- IBOC 3.8B
- CRSP 4.0B
- IPO Year
- IBOC N/A
- CRSP 2016
- Fundamental
- Price
- IBOC $69.28
- CRSP $48.29
- Analyst Decision
- IBOC
- CRSP Buy
- Analyst Count
- IBOC 0
- CRSP 17
- Target Price
- IBOC N/A
- CRSP $71.20
- AVG Volume (30 Days)
- IBOC 218.4K
- CRSP 3.5M
- Earning Date
- IBOC 07-31-2025
- CRSP 08-04-2025
- Dividend Yield
- IBOC 2.02%
- CRSP N/A
- EPS Growth
- IBOC 0.30
- CRSP N/A
- EPS
- IBOC 6.57
- CRSP N/A
- Revenue
- IBOC $803,860,000.00
- CRSP $37,675,000.00
- Revenue This Year
- IBOC N/A
- CRSP $30.25
- Revenue Next Year
- IBOC N/A
- CRSP $268.62
- P/E Ratio
- IBOC $10.13
- CRSP N/A
- Revenue Growth
- IBOC 1.14
- CRSP N/A
- 52 Week Low
- IBOC $54.11
- CRSP $30.04
- 52 Week High
- IBOC $76.91
- CRSP $63.68
- Technical
- Relative Strength Index (RSI)
- IBOC 62.53
- CRSP 65.82
- Support Level
- IBOC $66.11
- CRSP $45.60
- Resistance Level
- IBOC $67.25
- CRSP $51.52
- Average True Range (ATR)
- IBOC 1.39
- CRSP 2.29
- MACD
- IBOC 0.31
- CRSP 0.38
- Stochastic Oscillator
- IBOC 89.67
- CRSP 61.61
About IBOC International Bancshares Corporation
International Bancshares Corp is a multibank financial holding company. The company provides commercial and retail banking services in Texas and Oklahoma. The services provided by the bank include checking, savings, bank cards, lending, insurance, mortgage, investments, and other services.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.